Mereo BioPharma Group plc 8K

Mereo BioPharma announced first quarter 2026 results showing a reduced net loss, detailed mixed but supportive Phase 3 data and regulatory plans for setrusumab, outlined partnership-driven Phase 3 plans for alvelestat and development progress for vantictumab, and reaffirmed cash runway into mid-2027.

Mereo BioPharma Group plc reported its unaudited first quarter 2026 financial results, highlighting a narrowed net loss of $6.7 million versus $12.9 million a year earlier, R&D expense increases largely tied to setrusumab offset by reduced alvelestat spending, and significantly lower G&A expenses due to ADR reimbursements and delayed pre-commercial investments, while providing corporate updates that Phase 3 osteogenesis imperfecta trials for setrusumab missed primary fracture endpoints but met key secondary bone mineral density and patient-reported outcome measures, prompting ongoing regulatory discussions for a pediatric path forward, outlining plans for a single Phase 3 alvelestat trial in AATD-associated lung disease pending partnership, confirming continued advancement of vantictumab toward a Phase 2 trial in osteopetrosis by partner āshibio, and reaffirming cash runway of $36.2 million as of March 31, 2026 expected to fund operations into mid-2027.

Filing Facts

CIK

1719714

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-218290

Alert Tier

6